Note: This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

October 31, 2025

Company name: Zeria Pharmaceutical Co., Ltd.
Name of representative: Mitsuhiro Ibe,
Representative Director, President
(Securities code: 4559; Prime Market, TSE)
Inquiries: Koichi Tamura,
Director, Public Relations Division
(Telephone: +81-3-3661-1039)

Notice regarding Revision of Consolidated Earnings Forecast

Zeria Pharmaceutical Co., Ltd. (the "Company") hereby announces that it has revised the Company's consolidated earnings forecast for the six months ending September 30, 2025 announced on May 8, 2025, as follows.

1. Revisions to Consolidated Earnings Forecast

Revisions to Consolidated Earnings Forecast Figures for the First Six Months of the Fiscal Year Ending March 31, 2026 (April 1, 2025 to September 30, 2025)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	Million yen 43,000	Million yen 5,000	Million yen 5,000	Million yen 4,000	Yen 90.75
Revised forecast (B)	39,960	3,640	2,650	1,730	39.25
Change (B-A)	(3,040)	(1,360)	(2,350)	(2,270)	—
Change rate (%)	(7.1)	(27.2)	(47.0)	(56.8)	—
(Reference) Results for the previous fiscal year (Six months ended September 30, 2024)	42,422	6,459	7,949	6,061	137.51

2. Reasons for the Revision

For the First Six Months of the Fiscal Year Ending March 31, 2026, both sales and profits will fall below the initial forecasts. This outlook is due to a corrective decline in overseas markets following a significant increase in shipments during the fourth quarter of the previous fiscal year, along with issues with production equipment at the factory contracted to manufacture Asacol, which resulted in insufficient product supply for a certain period. However, the affected production equipment has been restored, and the product supply system is already back to normal. The Company expects a recovery to levels in line with the initial forecasts for the full-year. Furthermore, due to the sharp appreciation of the Swiss franc against European currencies such as the euro and British pound, significant foreign exchange losses are anticipated. Consequently, the decline in ordinary profit and profit attributable to owners of parent are expected to be greater than that in operating profit.

Regarding the full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, the Company

maintains the forecast announced on May 8, 2025, based on the expected recovery of its overseas pharmaceutical business, as described above. Given the uncertainty surrounding future exchange rates, the Company does not anticipate any foreign exchange gains or losses.
The Company will make a separate announcement if it becomes necessary to revise its earnings forecast.

(Note) The above forecasts are based on information available as of the date of this announcement. Actual results may differ from these forecasts due to a variety of factors in the future.

End